TCH GROUP, LLC for SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC )
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
General discussion regarding the reauthorization of the Prescription Drug User Fee Act (PDUFA)
Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Medicare/Medicaid MMM
General issues related to the Medicare Part D Program, issues related to provider reimbursement for the administration of vaccines.
Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Health Issues HCR
Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board (IBAP); awareness & issues related to diabetes and patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease"; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of Dengue; general issues related to prescription drug safety and the importation of prescription drugs; and all provisions of S1002 "Safe Doses Act"; awareness & issues related to patient access to care fo C. Difficile; awareness about the company's Access to Medicines Program; awareness & issues related to patient access to care for Dengue
Foreign entity interest: sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN HOLSCLAW | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.